Zibotentan/Dapagliflozin
- Generic Name
- Zibotentan/Dapagliflozin
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Phase 2
Recruiting
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 224
- Registration Number
- NCT06942910
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Phase 3
Active, not recruiting
- Conditions
- Chronic Kidney Disease With High Proteinuria
- Interventions
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1835
- Registration Number
- NCT06087835
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath